The market of traditional Chinese medicine formula granules will be further expanded, and pharmaceutical companies are rushing to the beach

With the continuous release of policy dividends, as well as the acceleration of the unified standard work of traditional Chinese medicine formula granules and the acceleration of inter-provincial joint procurement, China's traditional Chinese medicine formula granule market may be further expanded.
Some institutions predict that the traditional Chinese medicine formula granule market is expected to reach 100 billion yuan by 2030
.
In the face of the huge market, pharmaceutical companies have rushed to the beach
.
For example, more than 30 listed companies, such as Jilin Aodong, Yiling Pharmaceutical, Panlong Pharmaceutical, Kunyao Group, Tasly, Zhenbaodao Pharmaceutical, Essence Pharmaceutical, Zuoli Pharmaceutical, etc.
, have clearly laid out traditional Chinese medicine formula granules
.
Among them, on February 8, 2022, Jilin Aodong issued an announcement stating that Yanbian Pharmaceutical, a holding subsidiary, received 8 national standard "Chinese Medicine Formula Granules Listing Recording Certificates", including Angelica Formula Granules, Jiu Danshen Formula Granules,
etc.
According to the data, as of February 8, Jilin Aodong has obtained a total of 99 "Chinese Medicine Formula Granules Listing Recording Certificates"
.
In addition, Yiling Pharmaceutical once stated that the formula granule business is one of the business segments of the company's traditional Chinese medicine sector.
The company's research institute has completed the research and development of more than 180 formula granules in accordance with the new national standards.
Made a production record
.
Panlong Pharmaceutical once stated on the investor interaction platform that the company is currently actively exploring the development of traditional Chinese medicine formula granules, and has completed small-scale research on 17 traditional Chinese medicine formula granules such as Astragalus and Baishao
.
On January 13, Kunpharm Group stated on the investor interaction platform that the company's wholly-owned subsidiary, Kunzhong Medicine, was selected as a pilot enterprise of formula granules in Yunnan Province in 2018, and more than 300 formula granule varieties were approved
.
Tasly also stated on the investor interaction platform that the business of traditional Chinese medicine formula granules belongs to the business of listed companies
.
According to the Announcement No.
2020-016, "Announcement on Obtaining the Approval of Tianjin Food and Drug Administration for the Research and Production of Traditional Chinese Medicine Formula Granules", the market of traditional Chinese medicine formula granules has maintained a rapid growth trend in recent years.
The layout of the modern Chinese medicine industry chain, enriching the product structure, deepening the connection with the clinical practice of traditional Chinese medicine, expanding the brand effect, and further consolidating the dominant position in the industry
.
Zhenbaodao Pharmaceutical has successfully filed 550 formula granules of commonly used traditional Chinese medicines and obtained market access
.
More actively participate in the research and formulation of national standards and provincial standards for formula granules to ensure that Zhenbaodao Pharmaceutical's formula granules have strong competitiveness and market advantages in terms of quality and efficacy
.
With the layout of various enterprises, the market of traditional Chinese medicine formula granules will further expand
.
However, analysts also said that the market of traditional Chinese medicine formula granules is now in a pattern of "one super and many strong"
.
The first six pilot companies in the country, Guangdong Yifang (Chinese Traditional Medicine), Jiangyin Tianjiang (Chinese Traditional Medicine), China Resources Sanjiu, Hongri Pharmaceutical, Sichuan New Green Pharmaceutical, and Peili (Nanning) Pharmaceutical, still account for about 80% market share
.
It is understood that since the state issued the "Interim Regulations on the Administration of Traditional Chinese Medicine Formula Granules" in 2001, which included traditional Chinese medicine formula granules in the category of traditional Chinese medicine decoction pieces and carried out research and production by enterprises, until now, the traditional Chinese medicine formula granule industry has developed rapidly in China for more than 20 years.
The proportion of decoction pieces has also gradually increased.
For example, in 2020, the sales of TCM formula granules accounted for 11.
42% of the sales of TCM decoction pieces
.
In addition, according to the Ministry of Industry and Information Technology, the market size of traditional Chinese medicine formula granules in 2019 is about 50.
3 billion yuan, and in 2020, it is about 53.
3 billion yuan
.
According to the industry, with the changes in the competitive environment of the traditional Chinese medicine formula granule market and the continuous introduction of new policies, the market size of the industry will be further expanded, and more companies may enter the market in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.